These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2879304)

  • 1. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390.
    Hess EJ; Creese I
    Psychopharmacol Bull; 1986; 22(3):605-12. PubMed ID: 2879304
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple forms of the D1 dopamine receptor: its linkage to adenylate cyclase and psychopharmacological effects.
    Mailman RB; Schulz DW; Kilts CD; Lewis MH; Rollema H; Wyrick S
    Psychopharmacol Bull; 1986; 22(3):593-8. PubMed ID: 2879302
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia.
    Creese I; Hess EJ
    Clin Neuropharmacol; 1986; 9 Suppl 4():14-6. PubMed ID: 2882838
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of D1 and D2 dopamine antagonists on heroin-trained drug discrimination.
    Corrigall WA; Coen KM
    NIDA Res Monogr; 1989; 95():499. PubMed ID: 2577048
    [No Abstract]   [Full Text] [Related]  

  • 5. Structural analogs of SCH 23390 as discriminators of dopamine receptor subtypes: behavioral interactions between D-1 and D-2 agonists and antagonists.
    O'Boyle KM; Molloy AG; Mashurano M; Waddington JL
    Psychopharmacol Bull; 1986; 22(3):599-604. PubMed ID: 2879303
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The D1 dopamine receptor antagonist, SCH 23390 reduces locomotor activity and rearing in rats.
    Hoffman DC; Beninger RJ
    Pharmacol Biochem Behav; 1985 Feb; 22(2):341-2. PubMed ID: 2858871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.
    Sprah L; Zivin M; Sket D
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1093-100. PubMed ID: 10027846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dopamine D1 receptor: biochemical and behavioral aspects.
    Andersen PH; Nielsen EB
    Adv Exp Med Biol; 1986; 204():73-91. PubMed ID: 2878580
    [No Abstract]   [Full Text] [Related]  

  • 10. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.
    Iorio LC; Barnett A; Leitz FH; Houser VP; Korduba CA
    J Pharmacol Exp Ther; 1983 Aug; 226(2):462-8. PubMed ID: 6135795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dopamine D-1 antagonist SCH 23390 inhibits apomorphine but not pergolide induced rotation.
    Herrera-Marschitz M; Hyttel J; Ungerstedt U
    Acta Physiol Scand; 1984 Nov; 122(3):427-8. PubMed ID: 6240190
    [No Abstract]   [Full Text] [Related]  

  • 12. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of SCH 23390 on immobility behaviors in developing rats.
    Van Hartesveldt C; Meyer ME
    Dev Psychobiol; 1993 Sep; 26(6):335-43. PubMed ID: 8119483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that neuroleptics increase striatal acetylcholine release through stimulation of dopamine D1 receptors.
    Imperato A; Obinu MC; Casu MA; Mascia MS; Dazzi L; Gessa GL
    J Pharmacol Exp Ther; 1993 Aug; 266(2):557-62. PubMed ID: 8102643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioural differentiation between effects elicited at dopamine D-1 and D-2 receptors in rats.
    Arnt J; Hyttel J
    Clin Neuropharmacol; 1986; 9 Suppl 4():17-9. PubMed ID: 2952268
    [No Abstract]   [Full Text] [Related]  

  • 19. D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications.
    Clark D; White FJ
    Synapse; 1987; 1(4):347-88. PubMed ID: 2971273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injection of SCH 23390 into the ventral tegmental area blocks the development of neurochemical but not behavioral sensitization to cocaine.
    Steketee JD
    Behav Pharmacol; 1998 Feb; 9(1):69-76. PubMed ID: 9832950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.